![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The net financing will be used in advancing Invirsa's lead product candidate, INV-102, derived from a naturally occurring small molecule, in a series of Phase 2 studies in conditions including acute infectious keratoconjunctivitis, dry eye disease, and Fuchs corneal dystrophy.
Lead Product(s): Nadolol
Therapeutic Area: Ophthalmology Product Name: INV-102
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: CincyTech
Deal Size: $7.7 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 14, 2023